A detailed history of Northern Trust Corp transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 21,722 shares of CYTH stock, worth $14,988. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,722
Previous 21,722 -0.0%
Holding current value
$14,988
Previous $27,000 37.04%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.16 - $1.53 $22 - $29
-19 Reduced 0.09%
21,722 $27,000
Q1 2024

May 14, 2024

BUY
$1.39 - $1.9 $5,960 - $8,147
4,288 Added 24.57%
21,741 $30,000
Q4 2023

Feb 13, 2024

BUY
$0.93 - $1.88 $799 - $1,616
860 Added 5.18%
17,453 $27,000
Q2 2023

Aug 11, 2023

BUY
$0.67 - $2.3 $11,117 - $38,163
16,593 New
16,593 $26,000

Others Institutions Holding CYTH

About Cyclo Therapeutics, Inc.


  • Ticker CYTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 8,439,440
  • Market Cap $5.82M
  • Description
  • Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...
More about CYTH
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.